The Experts below are selected from a list of 1701 Experts worldwide ranked by ideXlab platform
Peter Rohdewald - One of the best experts on this subject based on the ideXlab platform.
-
(www.interscience.wiley.com) DOI: 10.1002/ptr.2461 Effect of Pine Bark Extract (Pycnogenol®) on Symptoms of Knee Osteoarthritis
2015Co-Authors: Copyright John Wiley, Jana Muchová, Iweta Waczulíková, Peter Cisár, Richard Jány, Katarína Sumegová, Jozef Vojtassák, Zdenka Duraçková, Miroslav Lisy, Peter RohdewaldAbstract:Objective. The safe and efficacious use of Pycnogenol ® (French maritime pine bark extract) in other inflam-matory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). The aim of the study was to evaluate whether Pycnogenol ® reduces the symptoms of OA in a double-blind, placebo-controlled, randomly allocated trial with patients suffering from knee osteoarthritis stages I and II. Methods. 100 patients were treated for 3 months either by 150 mg Pycnogenol ® per day at meals or by placebo. Patients had to report any change of use of previously prescribed antiinflammatory medication during the study period. Patients filled the Western Ontario and Mc Masters University (WOMAC) questionnaire for osteoarthritis every 2 weeks and evaluated weekly pain symptoms using a visual analogue scale for pain intensity. Results. Following treatment with Pycnogenol ® patients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. The use of analgesics diminished in the verum group but increased under the placebo. Treatment with Pycnogenol ® was well tolerated. Conclusion. Results show that Pycnogenol ® in patients with mild to moderate OA improves symptoms an
-
Pycnogenol treatment of acute hemorrhoidal episodes.
Phytotherapy research : PTR, 2009Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, B. M. Errichi, Andrea Di Renzo, M G Grossi, Andrea Ricci, Umberto Cornelli, Marisa Cacchio, Peter RohdewaldAbstract:We investigated the efficacy of orally and topically applied Pycnogenol for the management of acute hemorrhoidal attacks in a controlled, randomized study with 84 subjects. Within less than 48 h of onset of an acute attack, patients were enrolled and signs and symptoms were scored. This evaluation was repeated after seven days' treatment and again seven days following treatment cessation. The decrease in scores was significantly more pronounced in the Pycnogenol-treated groups than in the control group given placebo (p < 0.05), showing the efficacy of Pycnogenol for relieving signs and symptoms of acute external hemorrhoids. In a group of patients given topical (0.5%) Pycnogenol in addition to oral Pycnogenol the improvement in symptoms set in significantly faster and was more pronounced. The most prominent symptom, hemorrhoidal bleeding, was completely absent in all patients treated with Pycnogenol for seven days and also at the 14 days follow-up. In contrast, bleedings were still observed in the control group during the two weeks follow-up. This study indicates that Pycnogenol, both in oral and in topical form, is effective for controlling this common, disabling health problem. The application of Pycnogenol eases the management of acute hemorrhoidal attacks and help avoid bleedings.
-
effect of pine bark extract Pycnogenol on symptoms of knee osteoarthritis
Phytotherapy Research, 2008Co-Authors: Peter Cisár, Jana Muchová, Iweta Waczulíková, Richard Jány, Katarína Sumegová, Jozef Vojtassák, Miroslav Lisy, Zdenka ďurackova, Peter RohdewaldAbstract:®(French maritime pine bark extract) in other inflammatory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). The aim of the study was to evaluate whether Pycnogenol ® reduces the symptoms of OA in a double-blind, placebo-controlled, randomly allocated trial with patients suffering from knee osteoarthritis stages I and II. Methods. 100 patients were treated for 3 months either by 150 mg Pycnogenol ® per day at meals or by placebo. Patients had to report any change of use of previously prescribed antiinflammatory medication during the study period. Patients filled the Western Ontario and Mc Masters University (WOMAC) questionnaire for osteoarthritis every 2 weeks and evaluated weekly pain symptoms using a visual analogue scale for pain intensity. Results. Following treatment with Pycnogenol ® patients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. The use of analgesics diminished in the verum group but increased under the placebo. Treatment with Pycnogenol ® was well tolerated. Conclusion. Results show that Pycnogenol ® in patients with mild to moderate OA improves symptoms and
-
Effect of Pine Bark Extract (Pycnogenol ® ) on Symptoms of Knee Osteoarthritis
Phytotherapy research : PTR, 2008Co-Authors: Peter Cisár, Jana Muchová, Iweta Waczulíková, Richard Jány, Katarína Sumegová, Jozef Vojtassák, Miroslav Lisy, Zdenka Ďuračková, Peter RohdewaldAbstract:®(French maritime pine bark extract) in other inflammatory diseases prompted this study of its antiinflammatory effects in patients with osteoarthritis (OA). The aim of the study was to evaluate whether Pycnogenol ® reduces the symptoms of OA in a double-blind, placebo-controlled, randomly allocated trial with patients suffering from knee osteoarthritis stages I and II. Methods. 100 patients were treated for 3 months either by 150 mg Pycnogenol ® per day at meals or by placebo. Patients had to report any change of use of previously prescribed antiinflammatory medication during the study period. Patients filled the Western Ontario and Mc Masters University (WOMAC) questionnaire for osteoarthritis every 2 weeks and evaluated weekly pain symptoms using a visual analogue scale for pain intensity. Results. Following treatment with Pycnogenol ® patients reported an improvement of WOMAC index (p < 0.05), and a significant alleviation of pain by visual analogue scale (p < 0.04), the placebo had no effect. The use of analgesics diminished in the verum group but increased under the placebo. Treatment with Pycnogenol ® was well tolerated. Conclusion. Results show that Pycnogenol ® in patients with mild to moderate OA improves symptoms and
-
reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation
Nutrition Research, 2008Co-Authors: Sherma Zibadi, Peter Rohdewald, Danna Park, Ronald R WatsonAbstract:Patients with type 2 diabetes are at considerable risk of excessive morbidity and mortality from cardiovascular disease (CVD). We investigated the clinical effectiveness of Pycnogenol, a flavonoid-rich dietary supplement, in reducing antihypertensive medication use and CVD risk factors in subjects with type 2 diabetes. Forty-eight individuals were enrolled in a randomized, double-blind, placebo-controlled trial with parallel-group design. Patients were diagnosed with both type 2 diabetes and mild to moderate hypertension and were undergoing treatment with angiotensin-converting enzyme (ACE) inhibitors. Subjects were randomly assigned to receive either Pycnogenol pill (125 mg daily) or matched placebo for 12 weeks. According to the values of blood pressure (BP) measured at 2-week intervals, the pretrial ACE inhibitor dosage was left unchanged, reduced by 50%, or brought back to the pretrial dosage until a stable BP was obtained. Fasting plasma glucose, low-density lipoprotein (LDL) cholesterol, glycosylated hemoglobin (HbA1c), serum endothelin-1, and urinary albumin were evaluated monthly. Pycnogenol treatment achieved BP control in 58.3% of subjects at the end of the 12 weeks with 50% reduction in individual pretrial dose of ACE-inhibitors (P <.05). Plasma endothelin-1 decreased by 3.9 pg/mL in Pycnogenol-treated group vs 0.5 pg/mL increase in control group (P < .001). Mean HbA1c dropped by 0.8% in Pycnogenol-treated group (P < .05), whereas it decreased by 0.1% in control group. Fasting plasma glucose declined by 23.7 mg/dL in Pycnogenol-treated group vs 5.7 mg/dL in control group (P < .0001). Low-density lipoprotein cholesterol improved significantly in Pycnogenol-treated group, declining by 12.7 mg/dL (P < .001). A significant decrease in urinary albumin level was observed at week 8 compared with the control group (P < .05). However, this reduction was not significant at 12th week. After 12 weeks of supplementation, Pycnogenol resulted in improved diabetes control, lowered CVD risk factors, and reduced antihypertensive medicine use vs controls.
Gianni Belcaro - One of the best experts on this subject based on the ideXlab platform.
-
Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®.
Panminerva medica, 2021Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, Umberto Cornelli, Andrea Ledda, Morio Hosoi, Claudia Scipione, Valeria Scipione, Beatrice FeragalliAbstract:BACKGROUND The aim of this registry study was the prospective evaluation of the efficacy of Pycnogenol® in idiopathic fibromyalgia (FM), over 4 weeks in comparison with the standard management (SM). METHODS A SM and a Pycnogenol®+SM group were formed. Pycnogenol® supplementation was used at the dose of 150 mg/day (4 weeks). The study considered the most important/frequent symptoms of FM. RESULTS Fifty patients with idiopathic fibromyalgia were included: 26 in the Pycnogenol® group and 24 served as controls. The two groups were comparable at inclusion. No other disease or condition was present. All subjects were otherwise healthy women (BMI
-
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
Minerva cardioangiologica, 2019Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, Beatrice Feragalli, Roberto Cotellese, Hugh D. Bradford, Corrado Gizzi, Patrizia Rodriguez, Morio HosoiAbstract:BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode. Pycnogenol® is an anti-inflammatory, anti-edema, mild antiplatelet-antithrombotic agent. METHODS The registry study evaluated the number of repeated episodes of RVT in 12 months. Possible managements were: standard management (SM); SM + Aspirin (100 mg/once day; if there were no tolerability problems); SM + Pycnogenol (100 mg/day); SM and ticlopidine (200 mg/day); SM + sulodexide (500 ULS/day). The number of subjects age and sex, distribution, the percent of smokers, the vision were comparable at inclusion. RESULTS 307 subjects completed the study, 44 in the SM group, 90 in the Pycnogenol® group, 90 in the aspirin group, 45 in the ticlopidine group and 38 in the sulodexide group. At 12 months, recurrent RVT was documented in 22.7% of controls (SM), 3.3% of Pycnogenol® subjects (P
-
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
Minerva endocrinologica, 2019Co-Authors: Beatrice Feragalli, Gianni Belcaro, Mark Dugall, Roberta Luzzi, Andrea Ledda, Morio Hosoi, M. Rosaria CesaroneAbstract:BACKGROUND The aim of the present observational registry study was to evaluate the efficacy of a thin polycarbonate patch of Pycnogenol® in alleviating symptoms of knee arthrosis, in comparison to the standard management usually applied to treat osteoarthritis (OA). METHODS A total of 67 subjects were included in the registry: 34 formed the control group, and 33 entered the active management group in which the Pycnogenol® patch was used. Two Pycnogenol® patches were used every day for three weeks. Each patch contains 110 mg Pycnogenol®. All patients included in this registry suffered from osteoarthritis of the knee. RESULTS Results from this study show that Pycnogenol® patch allows faster improvement in OA symptoms, with a decrease in the use of non-steroidal anti-inflammatory drugs and other painkillers. Pycnogenol® patch significally reduced C reactive protein and ESR. CONCLUSIONS Pycnogenol® patch was effective in controlling mild to moderate pain and inflammations and its related symptoms in subjects with knee OA over a period of three weeks.
-
Chronic venous insufficiency and venous microangiopathy: management with compression and Pycnogenol®.
Minerva cardioangiologica, 2019Co-Authors: M. Rosaria Cesarone, Gianni Belcaro, Mark Dugall, Edmondo Ippolito, Beatrice Feragalli, Morio Hosoi, Marcello Corsi, Roberto Cotellese, Claudia ScipioneAbstract:BACKGROUND The aim of this prospective supplement summer registry study was to evaluate the efficacy of Pycnogenol® in controlling symptoms of chronic venous insufficiency (CVI) and microcirculatory parameters: venous hypertension and microangiopathy. Pycnogenol® (Horphag Research) is the standardized extract of the bark of Pinus Pinaster. METHODS During the summer period between June and August 142 patients were split into three groups: 1) Pycnogenol® 150 mg/day; 2) compression stockings; 3) and compression + Pycnogenol®. RESULTS Venous pressure (ambulatory venous pressure, AVP) and refilling time (RT), microcirculatory and clinical measurements were comparable at inclusion. At 8 weeks variations in skin flux (RF), rate of ankle swelling (RAS), skin PO2-PCO2, Analogue Symptomatic Score (ASLS), Venous Disability and severity Scores and local oxidative stress (OS) indicated a statistically significant improvement by Pycnogenol® both as a single supplement and in association with compression in comparison with baseline. Pycnogenol® significantly improved the microcirculation in comparison with compression (P
-
behcet syndrome effects of Pycnogenol supplementation during regression phases
Minerva Cardioangiologica, 2018Co-Authors: Gianni Belcaro, Mark Dugall, A Ledda, Beatrice Feragalli, Morio Hosoi, Roberto Cotellese, M. Corsi, Patrizia Torinorodriguez, M. Rosaria CesaroneAbstract:BACKGROUND The aim of this comparative registry study was to evaluate the supplementation with Pycnogenol® in subjects with Behcet syndrome (BS) with symptoms impairing their quality of life despite being in a remitting phase of the disease. METHODS Thirty-four patients with a confirmed diagnosis of BS were divided into the control group (without supplement) or the active group, in this specific case using Pycnogenol® (Horphag Research LTD) supplement at the daily dose of 150 mg (50 mg tid) for 4 weeks. RESULTS All subjects receiving Pycnogenol® reported a significant decrease in symptoms, such as burning/pain due to dryness and ulcerations (P<0.05). In addition, Pycnogenol® showed important anti-inflammatory activity by decreasing ESR, leucocytosis and Pathergy Test response. CONCLUSIONS Pycnogenol® may be a useful supplementation for the management of BS.
Ronald R Watson - One of the best experts on this subject based on the ideXlab platform.
-
Pycnogenol Supplementation and Cardiovascular Health: Treatment and Cost-Benefit Analysis
Nutrients Dietary Supplements and Nutriceuticals, 2010Co-Authors: Zaynah Tahmina Chowdhury, Sherma Zibadi, Frank Schonlau, Ronald R WatsonAbstract:Major risk factors for cardiovascular disease include hypertension, diabetes, dyslipidemia, endothelial function, and clotting abnormalities. Pycnogenol®, an extract of bark from the French maritime pine Pinus pinaster, is a clinically researched dietary supplement that counteracts several cardiovascular risk factors. Pycnogenol may be cost effective in reducing the risk for cardiovascular disease. The minimal side effects and health benefits associated with Pycnogenol may make it a suitable treatment for those wishing to reduce their risk for cardiovascular disease.
-
Cost of Pycnogenol Supplementation and Traditional Diabetes Treatments per Unit of Improved Health Outcome
Nutrients Dietary Supplements and Nutriceuticals, 2010Co-Authors: Gayle J. Bentley, Frank Schonlau, Sherma Zibadi, Ronald R WatsonAbstract:Pycnogenol® may be cost effective in reducing the risk for diabetes-related complications. Diabetic retinopathy may be a good target area for Pycnogenol supplementation because of Pycnogenol’s proven efficacy in improving diabetic retinopathy, diabetes-related cardiovascular disease, and other diabetes-related health complications. The cost of diabetes treatment may be reduced after Pycnogenol supplementation but a long term study should explore this possibility. The lack of side effects associated with Pycnogenol and demonstrated health benefits for diabetics may make it a suitable treatment for those wishing to reduce their risk for diabetes-related complications.
-
reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation
Nutrition Research, 2008Co-Authors: Sherma Zibadi, Peter Rohdewald, Danna Park, Ronald R WatsonAbstract:Patients with type 2 diabetes are at considerable risk of excessive morbidity and mortality from cardiovascular disease (CVD). We investigated the clinical effectiveness of Pycnogenol, a flavonoid-rich dietary supplement, in reducing antihypertensive medication use and CVD risk factors in subjects with type 2 diabetes. Forty-eight individuals were enrolled in a randomized, double-blind, placebo-controlled trial with parallel-group design. Patients were diagnosed with both type 2 diabetes and mild to moderate hypertension and were undergoing treatment with angiotensin-converting enzyme (ACE) inhibitors. Subjects were randomly assigned to receive either Pycnogenol pill (125 mg daily) or matched placebo for 12 weeks. According to the values of blood pressure (BP) measured at 2-week intervals, the pretrial ACE inhibitor dosage was left unchanged, reduced by 50%, or brought back to the pretrial dosage until a stable BP was obtained. Fasting plasma glucose, low-density lipoprotein (LDL) cholesterol, glycosylated hemoglobin (HbA1c), serum endothelin-1, and urinary albumin were evaluated monthly. Pycnogenol treatment achieved BP control in 58.3% of subjects at the end of the 12 weeks with 50% reduction in individual pretrial dose of ACE-inhibitors (P <.05). Plasma endothelin-1 decreased by 3.9 pg/mL in Pycnogenol-treated group vs 0.5 pg/mL increase in control group (P < .001). Mean HbA1c dropped by 0.8% in Pycnogenol-treated group (P < .05), whereas it decreased by 0.1% in control group. Fasting plasma glucose declined by 23.7 mg/dL in Pycnogenol-treated group vs 5.7 mg/dL in control group (P < .0001). Low-density lipoprotein cholesterol improved significantly in Pycnogenol-treated group, declining by 12.7 mg/dL (P < .001). A significant decrease in urinary albumin level was observed at week 8 compared with the control group (P < .05). However, this reduction was not significant at 12th week. After 12 weeks of supplementation, Pycnogenol resulted in improved diabetes control, lowered CVD risk factors, and reduced antihypertensive medicine use vs controls.
-
Pycnogenol supplementation reduces pain and stiffness and improves physical function in adults with knee osteoarthritis
Nutrition Research, 2007Co-Authors: Reza Farid, Peter Rohdewald, Sherma Zibadi, Zahra Mirfeizi, Mahyar Mirheidari, Zahra Rezaieyazdi, Hassan Mansouri, Habib Esmaelli, Ronald R WatsonAbstract:Knee osteoarthritis (OA) is a common degenerative joint disorder and a major cause of pain and disability. The purpose of this study was to investigate the potential effect of Pycnogenol (Horphag Research, Ltd, Geneva, Switzerland), a flavonoid-rich dietary supplement, on the symptoms of knee OA. Thirty-seven osteoarthritic patients were enrolled in a randomized, double-blind, placebo-controlled trial with parallel-group design. Patients received either placebo or Pycnogenol pills (50 mg, three times daily) in a blinded fashion for 3 months. Osteoarthritis clinical symptoms were evaluated monthly with Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Nonsteroidal anti-inflammatory drugs (NSAIDs) or selective cyclooxygenase 2 (COX-2) inhibitors usage was also assessed. In the Pycnogenol group, there was a significant improvement in total WOMAC score and WOMAC subscale score of pain and physical function at 60 and 90 days of treatment. At 90 days, significant reduction of 43%, 35%, 52%, and 49% in self-reported pain, stiffness, physical function, and composite WOMAC score, respectively, were reported in Pycnogenol group, whereas the placebo group showed no significant changes. The dosage and frequency of NSAIDs or COX-2 inhibitors usage were increased in placebo group, which were significantly less in Pycnogenol group. The results of this study indicate the efficacy of Pycnogenol in alleviating osteoarthritis symptoms and reducing the need for NSAIDs or COX-2 inhibitors administration. This beneficial effect of Pycnogenol might be due to its antioxidant and anti-inflammatory properties. Further research is warranted to determine the underlying mechanism associated with this apparent effect.
-
Pycnogenol® and cardiovascular health
Evidence-Based Integrative Medicine, 2003Co-Authors: Ronald R WatsonAbstract:A vast number of pharmacological and clinical studies indicate that Pycnogenol®, a standardised extract of French maritime pine bark (Pinus pinaster), bears various favourable health benefits for the cardiovascular system. Pycnogenol is primarily composed of phenolic acids, derivatives of benzoic and cinnamic acid, and procyanidins. The latter are biopolymers of catechin and epicatechin subunits, which are recognised as important constituents in human nutrition. Bioavailability studies in humans show that Pycnogenol® constituents enter the blood stream as early as 2 hours after consumption and significantly increase the oxygen radical absorbance capacity (ORAC). In addition to the antioxidant activity, Pycnogenol enhances production of vasodilatory endothelial nitric oxide and prostacyclin. In contrast, serum concentration of vasoconstrictory mediators endothelin-1 and thromboxane are lowered in response to supplementation with Pycnogenol. This review gives an overview of clinical studies demonstrating that supplementation with Pycnogenol reduces platelet activity, lowers high blood pressure, relaxes artery constriction and improves blood circulation. Moreover, Pycnogenol reduces serum levels of low-density lipoproteins (LDL) cholesterol and increases high-density lipoproteins (HDL) cholesterol. We conclude that Pycnogenol has the potential to counteract all important cardiovascular risk factors simultaneously.
M. Rosaria Cesarone - One of the best experts on this subject based on the ideXlab platform.
-
Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®.
Panminerva medica, 2021Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, Umberto Cornelli, Andrea Ledda, Morio Hosoi, Claudia Scipione, Valeria Scipione, Beatrice FeragalliAbstract:BACKGROUND The aim of this registry study was the prospective evaluation of the efficacy of Pycnogenol® in idiopathic fibromyalgia (FM), over 4 weeks in comparison with the standard management (SM). METHODS A SM and a Pycnogenol®+SM group were formed. Pycnogenol® supplementation was used at the dose of 150 mg/day (4 weeks). The study considered the most important/frequent symptoms of FM. RESULTS Fifty patients with idiopathic fibromyalgia were included: 26 in the Pycnogenol® group and 24 served as controls. The two groups were comparable at inclusion. No other disease or condition was present. All subjects were otherwise healthy women (BMI
-
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
Minerva cardioangiologica, 2019Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, Beatrice Feragalli, Roberto Cotellese, Hugh D. Bradford, Corrado Gizzi, Patrizia Rodriguez, Morio HosoiAbstract:BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode. Pycnogenol® is an anti-inflammatory, anti-edema, mild antiplatelet-antithrombotic agent. METHODS The registry study evaluated the number of repeated episodes of RVT in 12 months. Possible managements were: standard management (SM); SM + Aspirin (100 mg/once day; if there were no tolerability problems); SM + Pycnogenol (100 mg/day); SM and ticlopidine (200 mg/day); SM + sulodexide (500 ULS/day). The number of subjects age and sex, distribution, the percent of smokers, the vision were comparable at inclusion. RESULTS 307 subjects completed the study, 44 in the SM group, 90 in the Pycnogenol® group, 90 in the aspirin group, 45 in the ticlopidine group and 38 in the sulodexide group. At 12 months, recurrent RVT was documented in 22.7% of controls (SM), 3.3% of Pycnogenol® subjects (P
-
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
Minerva endocrinologica, 2019Co-Authors: Beatrice Feragalli, Gianni Belcaro, Mark Dugall, Roberta Luzzi, Andrea Ledda, Morio Hosoi, M. Rosaria CesaroneAbstract:BACKGROUND The aim of the present observational registry study was to evaluate the efficacy of a thin polycarbonate patch of Pycnogenol® in alleviating symptoms of knee arthrosis, in comparison to the standard management usually applied to treat osteoarthritis (OA). METHODS A total of 67 subjects were included in the registry: 34 formed the control group, and 33 entered the active management group in which the Pycnogenol® patch was used. Two Pycnogenol® patches were used every day for three weeks. Each patch contains 110 mg Pycnogenol®. All patients included in this registry suffered from osteoarthritis of the knee. RESULTS Results from this study show that Pycnogenol® patch allows faster improvement in OA symptoms, with a decrease in the use of non-steroidal anti-inflammatory drugs and other painkillers. Pycnogenol® patch significally reduced C reactive protein and ESR. CONCLUSIONS Pycnogenol® patch was effective in controlling mild to moderate pain and inflammations and its related symptoms in subjects with knee OA over a period of three weeks.
-
Chronic venous insufficiency and venous microangiopathy: management with compression and Pycnogenol®.
Minerva cardioangiologica, 2019Co-Authors: M. Rosaria Cesarone, Gianni Belcaro, Mark Dugall, Edmondo Ippolito, Beatrice Feragalli, Morio Hosoi, Marcello Corsi, Roberto Cotellese, Claudia ScipioneAbstract:BACKGROUND The aim of this prospective supplement summer registry study was to evaluate the efficacy of Pycnogenol® in controlling symptoms of chronic venous insufficiency (CVI) and microcirculatory parameters: venous hypertension and microangiopathy. Pycnogenol® (Horphag Research) is the standardized extract of the bark of Pinus Pinaster. METHODS During the summer period between June and August 142 patients were split into three groups: 1) Pycnogenol® 150 mg/day; 2) compression stockings; 3) and compression + Pycnogenol®. RESULTS Venous pressure (ambulatory venous pressure, AVP) and refilling time (RT), microcirculatory and clinical measurements were comparable at inclusion. At 8 weeks variations in skin flux (RF), rate of ankle swelling (RAS), skin PO2-PCO2, Analogue Symptomatic Score (ASLS), Venous Disability and severity Scores and local oxidative stress (OS) indicated a statistically significant improvement by Pycnogenol® both as a single supplement and in association with compression in comparison with baseline. Pycnogenol® significantly improved the microcirculation in comparison with compression (P
-
behcet syndrome effects of Pycnogenol supplementation during regression phases
Minerva Cardioangiologica, 2018Co-Authors: Gianni Belcaro, Mark Dugall, A Ledda, Beatrice Feragalli, Morio Hosoi, Roberto Cotellese, M. Corsi, Patrizia Torinorodriguez, M. Rosaria CesaroneAbstract:BACKGROUND The aim of this comparative registry study was to evaluate the supplementation with Pycnogenol® in subjects with Behcet syndrome (BS) with symptoms impairing their quality of life despite being in a remitting phase of the disease. METHODS Thirty-four patients with a confirmed diagnosis of BS were divided into the control group (without supplement) or the active group, in this specific case using Pycnogenol® (Horphag Research LTD) supplement at the daily dose of 150 mg (50 mg tid) for 4 weeks. RESULTS All subjects receiving Pycnogenol® reported a significant decrease in symptoms, such as burning/pain due to dryness and ulcerations (P<0.05). In addition, Pycnogenol® showed important anti-inflammatory activity by decreasing ESR, leucocytosis and Pathergy Test response. CONCLUSIONS Pycnogenol® may be a useful supplementation for the management of BS.
Mark Dugall - One of the best experts on this subject based on the ideXlab platform.
-
Idiopathic myalgic pain (fibromyalgia): supportive management and prevention with Pycnogenol®.
Panminerva medica, 2021Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, Umberto Cornelli, Andrea Ledda, Morio Hosoi, Claudia Scipione, Valeria Scipione, Beatrice FeragalliAbstract:BACKGROUND The aim of this registry study was the prospective evaluation of the efficacy of Pycnogenol® in idiopathic fibromyalgia (FM), over 4 weeks in comparison with the standard management (SM). METHODS A SM and a Pycnogenol®+SM group were formed. Pycnogenol® supplementation was used at the dose of 150 mg/day (4 weeks). The study considered the most important/frequent symptoms of FM. RESULTS Fifty patients with idiopathic fibromyalgia were included: 26 in the Pycnogenol® group and 24 served as controls. The two groups were comparable at inclusion. No other disease or condition was present. All subjects were otherwise healthy women (BMI
-
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
Minerva cardioangiologica, 2019Co-Authors: Gianni Belcaro, Mark Dugall, M. Rosaria Cesarone, Beatrice Feragalli, Roberto Cotellese, Hugh D. Bradford, Corrado Gizzi, Patrizia Rodriguez, Morio HosoiAbstract:BACKGROUND The aim of this study is to evaluate the use of Aspirin, Pycnogenol®, ticlopidine, and sulodexide to reduce the incidence of new RTV (retinal vein thrombosis) after a first episode. Pycnogenol® is an anti-inflammatory, anti-edema, mild antiplatelet-antithrombotic agent. METHODS The registry study evaluated the number of repeated episodes of RVT in 12 months. Possible managements were: standard management (SM); SM + Aspirin (100 mg/once day; if there were no tolerability problems); SM + Pycnogenol (100 mg/day); SM and ticlopidine (200 mg/day); SM + sulodexide (500 ULS/day). The number of subjects age and sex, distribution, the percent of smokers, the vision were comparable at inclusion. RESULTS 307 subjects completed the study, 44 in the SM group, 90 in the Pycnogenol® group, 90 in the aspirin group, 45 in the ticlopidine group and 38 in the sulodexide group. At 12 months, recurrent RVT was documented in 22.7% of controls (SM), 3.3% of Pycnogenol® subjects (P
-
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
Minerva endocrinologica, 2019Co-Authors: Beatrice Feragalli, Gianni Belcaro, Mark Dugall, Roberta Luzzi, Andrea Ledda, Morio Hosoi, M. Rosaria CesaroneAbstract:BACKGROUND The aim of the present observational registry study was to evaluate the efficacy of a thin polycarbonate patch of Pycnogenol® in alleviating symptoms of knee arthrosis, in comparison to the standard management usually applied to treat osteoarthritis (OA). METHODS A total of 67 subjects were included in the registry: 34 formed the control group, and 33 entered the active management group in which the Pycnogenol® patch was used. Two Pycnogenol® patches were used every day for three weeks. Each patch contains 110 mg Pycnogenol®. All patients included in this registry suffered from osteoarthritis of the knee. RESULTS Results from this study show that Pycnogenol® patch allows faster improvement in OA symptoms, with a decrease in the use of non-steroidal anti-inflammatory drugs and other painkillers. Pycnogenol® patch significally reduced C reactive protein and ESR. CONCLUSIONS Pycnogenol® patch was effective in controlling mild to moderate pain and inflammations and its related symptoms in subjects with knee OA over a period of three weeks.
-
Chronic venous insufficiency and venous microangiopathy: management with compression and Pycnogenol®.
Minerva cardioangiologica, 2019Co-Authors: M. Rosaria Cesarone, Gianni Belcaro, Mark Dugall, Edmondo Ippolito, Beatrice Feragalli, Morio Hosoi, Marcello Corsi, Roberto Cotellese, Claudia ScipioneAbstract:BACKGROUND The aim of this prospective supplement summer registry study was to evaluate the efficacy of Pycnogenol® in controlling symptoms of chronic venous insufficiency (CVI) and microcirculatory parameters: venous hypertension and microangiopathy. Pycnogenol® (Horphag Research) is the standardized extract of the bark of Pinus Pinaster. METHODS During the summer period between June and August 142 patients were split into three groups: 1) Pycnogenol® 150 mg/day; 2) compression stockings; 3) and compression + Pycnogenol®. RESULTS Venous pressure (ambulatory venous pressure, AVP) and refilling time (RT), microcirculatory and clinical measurements were comparable at inclusion. At 8 weeks variations in skin flux (RF), rate of ankle swelling (RAS), skin PO2-PCO2, Analogue Symptomatic Score (ASLS), Venous Disability and severity Scores and local oxidative stress (OS) indicated a statistically significant improvement by Pycnogenol® both as a single supplement and in association with compression in comparison with baseline. Pycnogenol® significantly improved the microcirculation in comparison with compression (P
-
behcet syndrome effects of Pycnogenol supplementation during regression phases
Minerva Cardioangiologica, 2018Co-Authors: Gianni Belcaro, Mark Dugall, A Ledda, Beatrice Feragalli, Morio Hosoi, Roberto Cotellese, M. Corsi, Patrizia Torinorodriguez, M. Rosaria CesaroneAbstract:BACKGROUND The aim of this comparative registry study was to evaluate the supplementation with Pycnogenol® in subjects with Behcet syndrome (BS) with symptoms impairing their quality of life despite being in a remitting phase of the disease. METHODS Thirty-four patients with a confirmed diagnosis of BS were divided into the control group (without supplement) or the active group, in this specific case using Pycnogenol® (Horphag Research LTD) supplement at the daily dose of 150 mg (50 mg tid) for 4 weeks. RESULTS All subjects receiving Pycnogenol® reported a significant decrease in symptoms, such as burning/pain due to dryness and ulcerations (P<0.05). In addition, Pycnogenol® showed important anti-inflammatory activity by decreasing ESR, leucocytosis and Pathergy Test response. CONCLUSIONS Pycnogenol® may be a useful supplementation for the management of BS.
